ANNA FARNAN: Open Payments
NPI 1427814664 · SHERWOOD, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,841 in 89 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $1,645 · 2025 $1,841
Food & beverage: $1,841
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 9 | $245 |
| ABBVIE INC. | 13 | $203 |
| Eisai Inc. | 11 | $162 |
| Novartis Pharmaceuticals Corporation | 7 | $124 |
| Neurocrine BioSciences, Inc. | 5 | $123 |
| Lilly USA, LLC | 6 | $118 |
| SK Life Science, Inc. | 4 | $109 |
| Neurelis, Inc. | 4 | $96 |
| SpringWorks Therapeutics, Inc. | 3 | $82 |
| CSL Behring | 3 | $81 |
Products named: Rystiggo, Leqembi, KESIMPTA, INGREZZA, AMYVID, VALTOCO, QULIPTA, UBRELVY.
Industry payments across AR — which companies pay providers there.
